[1]
|
中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组. 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0[J]. 中华肿瘤杂志, 2020, 42: 81-93. doi: 10.3760/cma.j.issn.0253-3766.2020.02.001
Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association. Chinese expert consensus on the surgical treatment of cutaneous / acral melanoma V 1.0[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 81-93. doi: 10.3760/cma.j.issn.0253-3766.2020.02.001 |
[2]
|
Gregson CL, Allain TJ. Amelanotic malignant melanoma disguised as a diabetic foot ulcer[J]. Diabet Med, 2004, 21: 924-927. doi: 10.1111/j.1464-5491.2004.01338.x |
[3]
|
Hussin P, Loke SC, Noor FM, et al. Malignant melanoma of the foot in patients with diabetes mellitus--a trap for the unwary[J]. Med J Malaysia, 2012, 67: 422-423. http://www.myjurnal.my/filebank/published_article/17871/MJM_2012_Paisal.pdf |
[4]
|
Tadiparthi S, Panchani S, Iqbal A. Biopsy for malignant melanoma--are we following the guidelines?[J]. Ann R Coll Surg Engl, 2008, 90: 322-325. doi: 10.1308/003588408X285856 |
[5]
|
中华医学会糖尿病学分会, 中华医学会感染病学分会, 中华医学会组织修复与再生分会. 中国糖尿病足防治指南(2019版)(Ⅱ)[J]. 中华糖尿病杂志, 2019, 11: 161-189. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX201911002.htm
Chinese Diabetes Soiety, Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition) (Ⅱ)[J]. Zhonghua Tangniaobing Zazhi, 2019, 11: 161-189. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX201911002.htm |
[6]
|
Qi L, Qi X, Xiong H, et al. Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies[J]. Iran J Public Health, 2014, 43: 857-866. http://ijph.tums.ac.ir/index.php/ijph/article/download/4016/3675 |
[7]
|
王璐宁, 关小宏, 吴石白, 等. 以糖尿病足为表现的足趾恶性黑色素瘤一例[J]. 中国医药, 2013, 8: 878. doi: 10.3760/cma.j.issn.1673-4777.2013.06.063
Wang LN, Guan XH, Wu SB, et al. A case of toe malignant melanoma characterized by diabetic foot[J]. Zhongguo Yiyao, 2013, 8: 878. doi: 10.3760/cma.j.issn.1673-4777.2013.06.063 |
[8]
|
高小华, 裔华. 1例糖尿病足5年并发黑色素瘤合并下肢丹毒患者的护理[J]. 实用临床医药杂志, 2018, 22: 130-132. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201818039.htm
Gao XH, Yi H. Nursing care of one patients with diabetic foot of 5 years with melanoma and erysipelas in lower extremities[J]. Shiyong Linchuang Yiyao Zazhi, 2018, 22: 130-132. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201818039.htm |
[9]
|
孙丽岩, 王泳. 晚期黑色素瘤误诊糖尿病足1例报告[J]. 武警后勤学院学报(医学版), 2012, 21: 638-640. https://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201208022.htm
Sun LX, Wang Y. The report of one case of malignant melanoma in advanced stage with early symptom as paronychia which misdiagnosed as diabetic foot and literature review[J]. Wujing Houqin Xueyuan Xuebao (Yixueban), 2012, 21: 638-640. https://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201208022.htm |
[10]
|
王淑敏, 顾俊义, 顾雪明, 等. 糖尿病足截趾术后残端并发黑色素瘤一例[J]. 中华内分泌代谢杂志, 2016, 32: 956-958. doi: 10.3760/cma.j.issn.1000-6699.2016.11.013
Wang SM, Gu JY, Gu XM, et al. A case of malignant melanoma occurring in the diabetic foot amputation site[J]. Zhonghua Neifenmi Daixie Zazhi, 2016, 32: 956-958. doi: 10.3760/cma.j.issn.1000-6699.2016.11.013 |
[11]
|
刘东, 伦立德. 血液透析患者恶性黑色素瘤误诊为糖尿病足坏疽1例报道[J]. 中国血液净化, 2007, 6: 687. doi: 10.3969/j.issn.1671-4091.2007.12.016
Liu D, Lun LD. Malignant melanoma misdiagnosed as diabetic foot gangrene in hemodialysis patients: a case report[J]. Zhongguo Xueye Jinghua, 2007, 6: 687. doi: 10.3969/j.issn.1671-4091.2007.12.016 |
[12]
|
Zaidi MS, Hassan A, Ouizi S. Can a diabetic foot be malignant?[J]. J Pak Med Assoc, 2016, 66: 1487-1489. http://www.ncbi.nlm.nih.gov/pubmed/27812075 |
[13]
|
Gao W, Chen D, Ran X. Malignant melanoma misdiagnosed as diabetic foot ulcer: A case report[J]. Medicine (Baltimore), 2017, 96: e7541. doi: 10.1097/MD.0000000000007541 |
[14]
|
Torres T, Rosmaninho A, Caetano M, et al. Malignant melanoma misdiagnosed as a diabetic foot ulcer[J]. Diabet Med, 2010, 27: 1302-1303. doi: 10.1111/j.1464-5491.2010.03102.x |
[15]
|
Rogers LC, Armstrong DG, Boulton AJ, et al. Malignant melanoma misdiagnosed as a diabetic foot ulcer[J]. Diabetes Care, 2007, 30: 444-445. |
[16]
|
Scarfì F, Galeone M, Bassi A, et al. Melanoma manifesting as a verrucous lesion in the interdigital toe space[J]. Int J Dermatol, 2014, 53: 1125. doi: 10.1111/ijd.12638 |
[17]
|
Gencoglan G, Inanir I, Miskioglu M, et al. Acral amelanotic verrucous melanoma: dermoscopic findings[J]. Dermatol Surg, 2011, 37: 107. doi: 10.1111/j.1524-4725.2010.01828.x |
[18]
|
Choi YD, Chun SM, Jin SA, et al. Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses[J]. J Am Acad Dermatol, 2013, 69: 700. doi: 10.1016/j.jaad.2013.06.035 |
[19]
|
Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies[J]. Eur J Cancer, 2013, 49: 642-657. doi: 10.1016/j.ejca.2012.08.028 |
[20]
|
Antoniadis AG, Petridou ET, Antonopoulos CN, et al. Insulin resistance in relation to melanoma risk[J]. Melanoma Res, 2011, 21: 541-546. doi: 10.1097/CMR.0b013e32834b0eeb |
[21]
|
Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth[J]. Endocr Rev, 2000, 21: 215-244. doi: 10.1210/edrv.21.3.0399 |
[22]
|
Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases[J]. Med Hypotheses, 2004, 63: 449-452. doi: 10.1016/j.mehy.2004.02.042 |
[23]
|
Sharma SD, Katiyar SK. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin[J]. Toxicol Appl Pharmacol, 2010, 44: 328-335. http://www.cabdirect.org/abstracts/20103135333.html |
[24]
|
Grineva EN, Karonova T, Micheeva E, et al. Vitamin D deficiency is a risk factor for obesity and diabetes type 2 in women at late reproductive age[J]. Aging (Albany NY), 2013, 5: 575-581. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765584/pdf/aging-05-575.pdf |
[25]
|
Li L, Wu B, Liu JY, et al. Vitamin D receptor gene polymorphisms and type 2 diabetes: a meta-analysis[J]. Arch Med Res, 2013, 44: 235-241. doi: 10.1016/j.arcmed.2013.02.002 |
[26]
|
Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma[J]. Clin Cancer Res, 2000, 6: 498-504. http://pdfs.semanticscholar.org/5de6/a74f13a60f1b4141b08de1bf4faabe74fc33.pdf |
[27]
|
Wysoczańska-Klaczyńska A, Ślęzak A, Hetman M, et al. The impact of VDR gene polymorphisms on obesity, meta-bolic changes, bone mass disorders and neoplastic processes[J]. Pediatr Endocrinol Diabetes Metab, 2018, 24: 96-105. doi: 10.18544/PEDM-24.02.0108 |
[28]
|
CSCO黑色素瘤专家委员会. 中国黑色素瘤诊治指南(2011版)[J]. 临床肿瘤学杂志, 2012, 17: 159-171. doi: 10.3969/j.issn.1009-0460.2012.02.015
Experts Committee on Malignant Melanoma. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2011 Edition)[J]. Linchuang Zhongliuxue Zazhi, 2012, 17: 159-171. doi: 10.3969/j.issn.1009-0460.2012.02.015 |
[29]
|
陈云, 赵静雯, 唐缨. 肝转移性恶性黑色素瘤超声表现1例[J]. 中国超声医学杂志, 2018, 34: 185-186. doi: 10.3969/j.issn.1002-0101.2018.02.029
Chen Y, Zhao JW, Tang Y. Ultrasonographic features of metastatic melanoma of the liver: a case report[J]. Zhongguo Chaosheng Yixue Zazhi, 2018, 34: 185-186. doi: 10.3969/j.issn.1002-0101.2018.02.029 |
[30]
|
夏波. 视网膜黑色素瘤肝转移误诊为肝硬化一例[J]. 中外医疗, 2009, 28: 172. https://www.cnki.com.cn/Article/CJFDTOTAL-HZZZ200907141.htm
Xia B. A case of hepatic metastasis of retinal melanoma misdiagnosed as liver cirrhosis[J]. Zhongwai Yiliao, 2009, 28: 172. https://www.cnki.com.cn/Article/CJFDTOTAL-HZZZ200907141.htm |
[31]
|
Cancer Research UK. Melanoma skin cancer[EB/OL]. (2020-03-25)[2020-05-13]. https://www.cancerresearchuk.org/about-cancer/melanoma/survival. |
[32]
|
Helgadottir H, Rocha Trocoli DrakensjöI, Girnita A. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment[J]. Front Oncol, 2018, 8: 202. doi: 10.3389/fonc.2018.00202 |
[33]
|
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16: 522-530. doi: 10.1016/S1470-2045(15)70122-1 |
[34]
|
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2015, 16: 908-918. doi: 10.1016/S1470-2045(15)00083-2 |
[35]
|
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372: 320-330. doi: 10.1056/NEJMoa1412082 |
[36]
|
Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet, 2015, 386: 444-451. doi: 10.1016/S0140-6736(15)60898-4 |
[37]
|
Karlin NJ, Mangold AR, Amin SB, et al. Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus[J]. Future Sci OA, 2019, 5: FSO368. doi: 10.4155/fsoa-2018-0084 |